Friday, August 25, 2023
Radiopharm Theranostics announced an expanded agreement with TerThera to supply Terbium-161 (Tb-161) for treatment of advanced prostate cancer.
The supply arrangement spans an initial duration of three years, open to extension for an additional two years. The first agreement with TerThera was signed in April 2023 to use RAD 602 for brain cancer. Now, the plan is to enhance this by creating a second compound connected to Terbium-161.
Tb-161 exhibits remarkable preclinical outcomes when compared to Lu-177, potentially leading to increased absorbed doses within micrometastatic ailments while minimising renal toxicity. This innovative radiopharmaceutical holds promise as the pioneering KLK-based theranostic alternative for individuals grappling with progressive prostate cancer.
RAD 402, developed by Radiopharmaceuticals (Radiopharm), combines the Tb-161 isotope and a unique monoclonal antibody (mAb) to create a radiotherapeutic. This innovative treatment is designed to specifically target KLK3 expression. KLK3 is prominently found in prostate cancer cells but has minimal presence in healthy tissues.
The Phase I clinical trial focused on evaluating the safety and efficacy of RAD 402 in patients with advanced prostate cancer will be scheduled during the second half of 2024.
